The Partial Dependency of Human Prostatic Growth Factor on Steroid Hormones in Stimulating Thymidine Incorporation into Dna

Hierowski, Marion T.; McDonald, Malcolm; Dunn, Lily; Sullivan, Jeremy A.

doi:10.1016/s0022-5347(17)43414-8

Cited by 30 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whether these authors have independently described the same factor or a family of factors is unclear. The concentration of this factor in prostate cancer is similar to that found in benign prostatic hypertrophy, but three to five times higher than in normal prostatic tissue 120 . The effect of growth factor on 3 H‐thymidine uptake was greatest with prostatic adenocarcinoma tissue 121 .…”

Section: Growthsupporting

confidence: 54%

“…The effect of growth factor on 3 H‐thymidine uptake was greatest with prostatic adenocarcinoma tissue 121 . In addition, another group found apparent synergism between this growth factor and androgens 120 . The relationship between androgens and prostatic growth factor is unclear, and a direct controlling influence, as found with EGF, has not been shown.…”

Section: Growthmentioning

confidence: 99%

See 1 more Smart Citation

Prostatic Adenocarcinoma Carcinogenesis and Growth

Moon¹,

Sloane²

1989

J American Geriatrics Society

View full text Add to dashboard Cite

Section: Growthsupporting

confidence: 54%

Section: Growthmentioning

confidence: 99%

Prostatic Adenocarcinoma Carcinogenesis and Growth

Moon¹,

Sloane²

1989

J American Geriatrics Society

View full text Add to dashboard Cite

“…Normal prostate growth is regulated by the interaction between epithelium and stroma via stimulatory or inhibitory peptide growth factors in the presence of androgens. Epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), and transforming growth factor alpha (TGF-␣) are involved [28], and EGF and bFGF may account for >80% of the positive modulation of prostate growth [29]. The members of the transforming growth factor family can either promote or inhibit cell growth in different situations.…”

Section: Discussionmentioning

confidence: 99%

Transforming growth factor-β3 is expressed in nondividing basal epithelial cells in normal human prostate and benign prostatic hyperplasia, and is no longer detectable in prostate carcinoma

et al. 1997

View full text Add to dashboard Cite

BACKGROUND We investigated the role of the transforming growth factor beta (TGF‐β) family in the neoplastic progression of the human prostate. METHODS Expression of TGF‐β mRNA was measured by Northern blot analysis of tissue extracts, and TGF‐β protein by immunohistochemical analysis of tissue sections. Proliferating cells were detected by their expression of Ki‐67 antigen. RESULTS The level of TGF‐β1 mRNA was equal among normal prostate, benign prostatic hyperplasia (BPH), and prostate carcinoma. TGF‐β2 mRNA was not detectable, and TGF‐β3 mRNA was expressed 20‐fold lesion in carcinoma compared to BPH and normal prostate. TGF‐β1 protein was expressed in the stromal cells in all three tissues and TGF‐β3 protein in the basal layer of epithelial cells, but not in carcinoma. Proliferating epithelial cells fail to express TGF‐β3. CONCLUSIONS TGF‐β1 and TGF‐β3 are independently regulated, and carcinoma of the prostate is characterized by the loss of basal epithelial cells expressing TGF‐β3. Prostate 31:103–109, 1997. © 1997 Wiley‐Liss, Inc.

show abstract

“…Male sexual tissues show a profound dependence on the continuous presence of androgens for normal growth and function (5)(6)(7)(8). Whereas testosterone is produced by the testes, dihydrotestosterone (DHT) is produced from testosterone in tissues by an NADPH-dependent reaction catalyzed by the membrane-bound enzyme Sa-reductase [3-oxo-The publication costs of this article were defrayed in part by page charge payment.…”

mentioning

confidence: 99%

LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.

Hirsch

Jones

Audia

et al. 1993

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Androgens, in particular dihydrotestosterone (DHT), play a key role in differentiation, growth, and maintenance of the mammalian prostate. Production of DHT from testosterone is catalyzed by two distinct membrane-bound steroid 5a-reductase [5a-reductase; 3-oxo-5a-steroid A4-dehydrogenase; 3-oxo-5a-steroid:(acceptor) AW-oxidoreductase, EC 1.3.99.5] isozymes designated types 1 and 2. Benign prostatic hyperplasia (BPH), a disease that occurs almost universally in males, is characterized by obstructive and irritative urinary voiding symptoms and has been associated with an overproduction of DHT. Recently, steroidal inhibitors of 5a-reductase type 2 have been used successfully for treatment of BPH. Described here is a nonsteroidal inhibitor of 5a-reductase type 1, LY191704 {8-chloro-4-methyl-1,2,3,4,4a,5,6,10b-octaahydro-benzo[f]quinolin-3(2H)-one}. This compound was identified based on its capacity to inhibit 5a-reductase activity in a human genital skin fibroblast cell line (Hs68). Surprisingly, LY191704 is inactive when tested in freshly isolated prostate cells obtained from subjects with BPH, whereas previously described 4-azasteroids are active. LY191704 is, however, a potent inhibitor of the 5a-reductase activity of BPH cells that have been maintained in culture. Analysis of human and rat 5a-reductases expressed from transfected cDNAs in simian COS cells indicates that LY191704 is a specific noncompetitive inhibitor of the human 5a-reductase type 1. Taken together, the results suggest that prostate cells have the capacity to express both 5a-reductase isozymes and that LY191704 may be useful in treatment of human endocrine disorders associated with overproduction of DHT by 5a-reductase type 1.Prostatic hyperplasia is an age-related nonmalignant enlargement of the prostate that can result in development of obstructive and irritative urinary voiding symptoms (1, 2). For >100 years, prostatectomy has been used to treat benign prostatic hyperplasia (BPH) and is now the most common surgery performed in men >65 years old (3). Although prostatic surgery has been greatly refined, it still remains a significant cause of morbidity in elderly men (4). Recent attempts have, therefore, sought to develop pharmacological approaches for the treatment of BPH with the principal focus being on the development of agents that affect the underlying mechanisms leading to prostatic hyperplasia.Male sexual tissues show a profound dependence on the continuous presence of androgens for normal growth and function (5-8). Whereas testosterone is produced by the testes, dihydrotestosterone (DHT) is produced from testosterone in tissues by an NADPH-dependent reaction catalyzed by the membrane-bound enzyme Sa-reductase [3-oxo-The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. 5a-steroid A4-dehydrogenase; 3-oxo-5a-steroid:(acceptor) A4-oxidoreductase, EC 1.3.99.5] (9). Testosterone...

show abstract

The Partial Dependency of Human Prostatic Growth Factor on Steroid Hormones in Stimulating Thymidine Incorporation into Dna

Cited by 30 publications

References 10 publications

Prostatic Adenocarcinoma Carcinogenesis and Growth

Prostatic Adenocarcinoma Carcinogenesis and Growth

Transforming growth factor-β3 is expressed in nondividing basal epithelial cells in normal human prostate and benign prostatic hyperplasia, and is no longer detectable in prostate carcinoma

LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.

Contact Info

Product

Resources

About